Recent Finacing
Recent Raise
Tessellate BIO is a preclinical oncology company developing DNA damage response therapies beyond homologous recombination deficiency, with an ALT/FANCM lead program and CMRI/iMM-sourced pipeline, Netherlands HQ and UK labs.
